

10/636,070

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 Jul 12 BEILSTEIN enhanced with new display and select options,  
resulting in a closer connection to BABS  
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display  
fields  
NEWS 5 AUG 02 CAPLUS and CA patent records enhanced with European and Japan  
Patent Office Classifications  
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!  
(Version 7.01 for Windows) now available  
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage  
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal  
status data from INPADOC  
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available  
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX  
NEWS 12 SEP 14 STN Patent Forum to be held October 13, 2004, in Iselin, NJ  
NEWS 13 SEP 27 STANDARDS will no longer be available on STN  
NEWS 14 SEP 27 SWETSCAN will no longer be available on STN  
  
NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:32:11 ON 07 OCT 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:32:25 ON 07 OCT 2004  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4  
 DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
 information enter HELP PROP at an arrow prompt in the file or refer  
 to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>  
 Uploading C:\STNEXP4\QUERIES\10636070.str



```

chain nodes :
7 8 9 10 11
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17 20 21 22 23 24 25
chain bonds :
1-7 4-10 5-11 6-9 7-8 11-12 15-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 20-21
20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
1-2 1-6 1-7 2-3 3-4 4-5 4-10 5-6 6-9 12-13 12-17 13-14 14-15 15-16
15-20 16-17
exact bonds :
```

10/636,070

5-11 7-8 11-12

normalized bonds :

20-21 20-25 21-22 22-23 23-24 24-25

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 20:Atom 21:Atom  
22:Atom 23:Atom 24:Atom 25:Atom

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:32:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1 TO 80  
PROJECTED ANSWERS: 1 TO 80

L3 1 SEA SSS SAM L1

10/636,070

=> dscan

DSCAN IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.


For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> d scan

10/636,070

L3 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, hydrochloride (9CI)  
MF C21 H31 N5 O3 . x Cl H  
CI COM



● x HCl

ALL ANSWERS HAVE BEEN SCANNED

10/636,070

=> s l1 sss ful

FULL SEARCH INITIATED 17:33:03 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.01

L4 15 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 17:33:08 ON 07 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15

FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4


L5 19 L4

=> d l5 1-19 bib hitstr

L5 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2004:480119 CAPLUS  
 DN 141:175822  
 TI Development of a Safe and Scalable Oxidation Process for the Preparation of 6-Hydroxybuspirone: Application of In-Line Monitoring for Process Ruggedness and Product Quality  
 AU Watson, Daniel J.; Dowdy, Eric D.; DePue, Jeffrey S.; Kotnis, Atul S.; Leung, Simon; O'Reilly, Brian C.  
 CS Department of Process Research and Development, Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ, 08903, USA  
 SO Organic Process Research & Development (2004), 8(4), 616-623  
 CODEN: OPRDFK; ISSN: 1083-6160  
 PB American Chemical Society  
 DT Journal  
 LA English  
 IT **658701-59-8P**  
 RL: BYP (Byproduct); PREP (Preparation)  
 (development of safe and scalable oxidation process for preparation of 6-hydroxybuspirone using online monitoring for process ruggedness and product quality)  
 RN 658701-59-8 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6,10-dihydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



IT **125481-61-0P**, 6-Hydroxybuspirone  
 RL: IMF (Industrial manufacture); PREP (Preparation)  
 (development of safe and scalable oxidation process for preparation of 6-hydroxybuspirone using online monitoring for process ruggedness and product quality)  
 RN 125481-61-0 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:452952 CAPLUS

DN 141:1296

TI Method of using a cyclooxygenase 2 (COX-2) inhibitor and a 5-HT<sub>1A</sub> receptor modulator as a combination therapy for pain, inflammation, and other conditions

IN Stephenson, Diane T.; Taylor, Duncan P.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 195 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004045509	A2	20040603	WO 2003-US35739	20031111
	WO 2004045509	A3	20040826		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004147581	A1	20040729	US 2003-702403	20031105
PRAI	US 2002-427198P	P	20021118		
IT	<b>125481-61-0</b> , 6-Hydroxybuspirone				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(COX2 inhibitor-5-HT <sub>1A</sub> modulator combination for treatment of pain, inflammation, and other conditions)				
RN	125481-61-0 CAPLUS				
CN	8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)				





L5 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:142906 CAPLUS

DN 140:181468

TI Improved process for preparing hydroxyazapirones by deprotonation of azapirones with a strong base, and hydroxylation of the in-situ formed enolate with O<sub>2</sub> in the presence of a reductant

IN Depue, Jeffrey; Kotnis, Atul S.; Leung, Simon; Dowdy, Eric D.; Watson, Daniel J.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 17 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014309	A2	20040219	WO 2003-US24934	20030807
	WO 2004014309	A3	20040624		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004067958	A1	20040408	US 2003-636070	20030807
PRAI	US 2002-402759P	P	20020812		
OS	MARPAT 140:181468				
IT	<b>658701-59-8P</b> , 6,10-Dihydroxybuspirone				
	RL: BYP (Byproduct); PUR (Purification or recovery); PREP (Preparation) (dihydroxyazapirone side product; process for preparation of hydroxyazapirones by deprotonation of azapirones with strong base, and hydroxylation of in-situ formed enolate with O <sub>2</sub> in presence of reductant)				
RN	658701-59-8 CAPLUS				
CN	8-Azaspiro[4.5]decane-7,9-dione, 6,10-dihydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)				

IT **125481-61-0P**, 6-Hydroxybuspirone


RL: IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); PREP (Preparation); PROC (Process)

(hydroxyazapirone product; process for preparation of hydroxyazapirones by deprotonation of azapirones with strong base, and hydroxylation of

in-situ formed enolate with O<sub>2</sub> in presence of reductant)

RN 125481-61-0 CAPLUS

CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




IT **345894-78-2P**, 3-Hydroxygepirone

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(hydroxyazapirone product; process for preparation of hydroxyazapirones by deprotonation of azapirones with strong base, and hydroxylation of in-situ formed enolate with O<sub>2</sub> in presence of reductant)


RN 345894-78-2 CAPLUS

CN 2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



10/636,070

L5 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:682663 CAPLUS  
DN 140:314318  
TI Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs  
AU Faassen, Fried; Vogel, Gerard; Spanings, Henry; Vromans, Herman  
CS Department of Pharmaceutics (RP2205), NV Organon, Oss, 5340 BH, Neth.  
SO International Journal of Pharmaceutics (2003), 263(1-2), 113-122  
CODEN: IJPHDE; ISSN: 0378-5173  
PB Elsevier Science B.V.  
DT Journal  
LA English  
IT **678993-23-2**, Org 25907  
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs)  
RN 678993-23-2 CAPLUS  
CN 2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:282120 CAPLUS  
 DN 138:281137  
 TI Antianxiety composition using BMY 28674, and preparation thereof  
 IN Yevich, Joseph P.; Mayol, Robert F.; Li, Jianqing; Ruediger, Edward H.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 588,220.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003069251	A1	20030410	US 2002-201733	20020723
	US 2001009913	A1	20010726	US 2001-802331	20010308
PRAI	US 1999-368842	B3	19990805		
	US 2000-484161	B2	20000118		
	US 2000-588220	B2	20000606		
	US 2000-588223	B1	20000606		
IT	<b>125481-61-0P</b> , BMY 28674				
	RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(BMY 28674 anti-anxiety composition, and BMY 28674 preparation)				
RN	125481-61-0 CAPLUS				
CN	8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)				



IT **477930-34-0**  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (BMY 28674 anti-anxiety composition, and BMY 28674 preparation)  
 RN 477930-34-0 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, hydrochloride (9CI) (CA INDEX NAME)

10/636,070



•x HCl

L5 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:221392 CAPLUS

DN 139:173122

TI Human cytochromes mediating gepirone biotransformation at low substrate concentrations

AU Greenblatt, David J.; von Moltke, Lisa L.; Giancarlo, Gina M.; Garteiz, Daniel A.

CS Department of Pharmacology and Experimental Therapeutics, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, 02111, USA

SO Biopharmaceutics & Drug Disposition (2003), 24(2), 87-94  
CODEN: BDDID8; ISSN: 0142-2782

PB John Wiley & Sons Ltd.

DT Journal

LA English


IT **345894-78-2**

RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL (Biological study)

(gepirone biotransformation at low substrate concns. by cytochrome P 450 isoforms in human liver microsomes to form)

RN 345894-78-2 CAPLUS

CN 2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:97305 CAPLUS  
 DN 138:131155  
 TI R-6-hydroxybuspirone for the treatment of anxiety, depression, and other psychogenic disorders  
 IN Yevich, Joseph P.; Mayol, Robert F.; Li, Jianqing; Yocca, Frank  
 PA Bristol-Myers Squibb Company, USA  
 SO PCT Int. Appl., 19 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003009851	A1	20030206	WO 2002-US23342	20020722
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003055063	A1	20030320	US 2002-200931	20020722
	US 6686361	B2	20040203		
	EP 1408979	A1	20040421	EP 2002-750251	20020722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	US 2001-307431P	P	20010724		
	WO 2002-US23342	W	20020722		
IT	<b>477930-31-7</b>				
	RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)				
	(R-6-hydroxybuspirone for treatment of anxiety, depression, and other psychogenic disorders)				
RN	477930-31-7 CAPLUS				
CN	8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (6S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT **477930-30-6P**  
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN

10/636,070


(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);  
PREP (Preparation); USES (Uses)

(R-6-hydroxybuspirone for treatment of anxiety, depression, and other  
psychogenic disorders)

RN 477930-30-6 CAPLUS

CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-  
piperazinyl]butyl]-, (6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:77553 CAPLUS  
 DN 138:131151  
 TI S-6-Hydroxy-buspirone for treatment of anxiety, depression and related disorders  
 IN Yevich, Joseph P.; Mayol, Robert F.; Li, Jianqing; Yocca, Frank  
 PA USA  
 SO U.S. Pat. Appl. Publ., 7 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003022899	A1	20030130	US 2002-201063	20020722
	WO 2003010161	A1	20030206	WO 2002-US23341	20020722
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1417203	A1	20040512	EP 2002-747078	20020722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	US 2001-307428P	P	20010724		
	WO 2002-US23341	W	20020722		
IT	<b>125481-61-0P</b>				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(S-isomer of hydroxybuspirone for treatment of anxiety, depression and related disorders)				
RN	125481-61-0 CAPLUS				
CN	8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)				




IT **477930-31-7P**  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (S-isomer of hydroxybuspirone for treatment of anxiety, depression and related disorders)

10/636,070

RN 477930-31-7 CAPLUS

CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




10/636,070

L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:965125 CAPLUS  
DN 138:19523  
TI Method using acetaminophen and a hydroxyazapirone for treatment of pain  
IN Camborde, Francoise; Cloarec, Alix; Conway, Charles  
PA Fr.  
SO U.S. Pat. Appl. Publ., 12 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002193380	A1	20021219	US 2002-115785	20020404
	US 6593331	B2	20030715		
PRAI	US 2001-284425P	P	20010417		
IT	<b>125481-61-0P 345894-78-2P, 3-Hydroxygepirone</b> <b>477930-30-6P 477930-31-7P 477930-32-8P</b> <b>477930-33-9P</b> RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (acetaminophen-hydroxyazapirone combination for treatment of pain)				
RN	125481-61-0	CAPLUS			
CN	8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)				




RN 345894-78-2 CAPLUS  
CN 2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 477930-30-6 CAPLUS  
CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477930-31-7 CAPLUS

CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477930-32-8 CAPLUS

CN 2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477930-33-9 CAPLUS

CN 2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 477930-34-0 477930-35-1 477930-36-2  
477930-37-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(acetaminophen-hydroxyzapirone combination for treatment of pain)

RN 477930-34-0 CAPLUS


CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 477930-35-1 CAPLUS

CN 2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 477930-36-2 CAPLUS


CN Acetamide, N-(4-hydroxyphenyl)-, mixt. with 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione hydrochloride (9CI) (CA INDEX NAME)

10/636,070

CM 1

CRN 477930-35-1

CMF C19 H29 N5 O3 . x Cl H




● x HCl

CM 2

CRN 103-90-2

CMF C8 H9 N O2




RN 477930-37-3 CAPLUS

CN Acetamide, N-(4-hydroxyphenyl)-, mixt. with 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 477930-34-0

CMF C21 H31 N5 O3 . x Cl H




● x HCl

CM 2


10/636,070

CRN 103-90-2  
CMF C8 H9 N O2



10/636,070

L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:713913 CAPLUS  
DN 137:362481  
TI Pharmacokinetics of gepirone in subjects with normal renal function and in patients with chronic renal dysfunction  
AU Dogterom, Peter; Huisman, Jan A. M.; Gellert, Ryszard; Verhagen, Aalt  
CS Department of Clinical Pharmacology, NV Organon, Oss, Neth.  
SO Clinical Drug Investigation (2002), 22(8), 513-522  
CODEN: CDINFR; ISSN: 1173-2563  
PB Adis International Ltd.  
DT Journal  
LA English  
IT **345894-78-2**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(gepirone pharmacokinetics in normal renal function and chronic renal dysfunction patients: urine and plasma concentration of metabolites)  
RN 345894-78-2 CAPLUS  
CN 2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:428709 CAPLUS  
 DN 137:745  
 TI 1,7,7-Trimethylbicyclo[2.2.1]heptane derivatives for combination therapy  
 of serotonergic disorders  
 IN Maki-Ikola, Outi  
 PA Orion Corporation, Finland  
 SO PCT Int. Appl., 13 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002043724	A1	20020606	WO 2001-FI1029	20011127
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,				
	UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002018335	A5	20020611	AU 2002-18335	20011127
PRAI	FI 2000-2612	A	20001128		
	WO 2001-FI1029	W	20011127		
IT	<b>125481-61-0</b>				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL				
	(Biological study); USES (Uses)				
	(deramciclone and N-desmethylderamciclone for combination therapy of				
	serotonergic disorders)				
RN	125481-61-0 CAPLUS				
CN	8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-				
	piperazinyl]butyl]- (9CI) (CA INDEX NAME)				




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/636,070

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:157759 CAPLUS  
DN 136:216767  
TI 3-Hydroxygepirone, an active metabolite of gepirone, useful for treatment  
of depression and related disorders, and its preparation  
IN Rider, Peggy Hester; Ploemen, Joannes Hubertus Toussaint Maria; Hill,  
David Robert; Shahid, Mohammed; Ward, Nicholas Matthew; Drinkenburg,  
Wilhelmus Helena Ignatius Maria  
PA Akzo Nobel N.V., Neth.  
SO PCT Int. Appl., 18 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002016347	A1	20020228	WO 2001-EP9498	20010816
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001095478	A5	20020304	AU 2001-95478	20010816
PRAI	EP 2000-307224	A	20000822		
	WO 2001-EP9498	W	20010816		
OS	CASREACT 136:216767				
IT	345894-78-2P, 3-Hydroxygepirone				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of the gepirone metabolite 3-hydroxygepirone as an antidepressant and anxiolytic)				
RN	345894-78-2 CAPLUS				
CN	2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1- piperazinyl]butyl]- (9CI) (CA INDEX NAME)				



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:472475 CAPLUS  
 DN 135:56085  
 TI Methods for treating psychological disorders using bioactive metabolites of gepirone  
 IN Kramer, Stephen J.; Fabre, Louis F.  
 PA Fabre/Kramer Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001045687	A2	20010628	WO 2000-US34131	20001218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6534507	B1	20030318	US 2000-709741	20001113
	EP 1242061	A2	20020925	EP 2000-986449	20001218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004500362	T2	20040108	JP 2001-546426	20001218
	ZA 2002004765	A	20031112	ZA 2002-4765	20020613
	NO 2002002954	A	20020619	NO 2002-2954	20020619
	US 2003220346	A1	20031127	US 2003-149962	20030207
PRAI	US 1999-172684P	P	19991220		
	US 2000-709741	A	20001113		
	WO 2000-US34131	W	20001218		
IT	<b>345894-78-2P</b>				
	RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); USES (Uses)				
	(treating psychol. disorders using bioactive metabolites of gepirone)				
RN	345894-78-2 CAPLUS				
CN	2,6-Piperidinedione, 3-hydroxy-4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)				



IT **345894-80-6**  
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU


10/636,070

(Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

(treating psychol. disorders using bioactive metabolites of gepirone)

RN 345894-80-6 CAPLUS

CN 2,6-Piperidinedione, 3-hydroxy-1-[4-[4-(5-hydroxy-2-pyrimidinyl)-1-piperazinyl]butyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2000:819478 CAPLUS  
 DN 133:359250  
 TI Buspirone metabolite for the alleviation of anxiety  
 IN Mayol, Robert F.  
 PA Bristol-Myers Squibb Co., USA  
 SO U.S., 14 pp., Cont.-in-part of U. S. Ser. No. 484,161, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6150365	A	20001121	US 2000-588221	20000606
	WO 2001052853	A1	20010726	WO 2000-US28800	20001018
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	BR 2000016971	A	20021015	BR 2000-16971	20001018
	EP 1248622	A1	20021016	EP 2000-973636	20001018
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
	JP 2003520236	T2	20030702	JP 2001-552900	20001018
	NZ 520823	A	20040528	NZ 2000-520823	20001018
	US 2001009913	A1	20010726	US 2001-802331	20010308
	NO 2002003425	A	20020905	NO 2002-3425	20020717
PRAI	US 1999-368842	B3	19990805		
	US 2000-484161	B2	20000118		
	US 2000-588221	A	20000606		
	US 2000-588223	B1	20000606		
	WO 2000-US28800	W	20001018		


IT **125481-61-0P**

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); USES (Uses)

(buspirone metabolite for alleviation of anxiety)

RN 125481-61-0 CAPLUS


CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




10/636,070

RE.CNT 18      THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1997:573509 CAPLUS  
 DN 127:272173  
 TI Buspirone metabolite structure profile using a standard liquid chromatographic-mass spectrometric protocol  
 AU Kerns, Edward H.; Rourick, Robyn A.; Volk, Kevin J.; Lee, Mike S.  
 CS Bristol-Myers Squibb Pharmaceutical Research Institute, Building 105, 1 Squibb Drive, P.O. Box 191, New Brunswick, NJ, 08903-0191, USA  
 SO Journal of Chromatography, B: Biomedical Sciences and Applications (1997), 698(1 + 2), 133-145  
 CODEN: JCBEP; ISSN: 0378-4347  
 PB Elsevier  
 DT Journal  
 LA English  
 IT **125481-59-6 125481-60-9 125481-61-0**  
 RL: ANT (Analyte); BSU (Biological study, unclassified); MFM (Metabolic formation); PRP (Properties); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative)  
 (buspirone metabolite structure profile in urine and bile and liver using a standard liquid chromatog.-mass spectrometric protocol)  
 RN 125481-59-6 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(5-hydroxy-2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 125481-60-9 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(5-hydroxy-4-methoxy-2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 125481-61-0 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)


10/636,070




RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT




L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:455980 CAPLUS  
DN 125:104185  
TI Liquid Chromatography/Chemical Reaction Interface Mass Spectrometry as an  
Alternative to Radioisotopes for Quantitative Drug Metabolism Studies  
AU Goldthwaite, Charles A., Jr.; Hsieh, Feng-Yin; Womble, Scott W.; Nobes,  
Brian J.; Blair, Ian A.; Klunk, Lewis J.; Mayol, Robert F.  
CS Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232,  
USA  
SO Analytical Chemistry (1996), 68(17), 2996-3001  
CODEN: ANCHAM; ISSN: 0003-2700  
PB American Chemical Society  
DT Journal  
LA English  
IT **125481-61-0**, 6'-Hydroxybuspirone  
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL  
(Biological study); FORM (Formation, nonpreparative)  
(liquid chromatog./chemical reaction interface mass spectrometry using  
stable isotopes as alternative to radioisotopes for quant. drug metabolism  
studies using buspirone to validate method)  
RN 125481-61-0 CAPLUS  
CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-  
piperazinyl]butyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1990:584167 CAPLUS  
DN 113:184167  
TI In vitro metabolism of the antianxiety drug buspirone as a predictor of  
its metabolism in vivo  
AU Jajoo, H. K.; Blair, I. A.; Klunk, L. J.; Mayol, R. F.  
CS Sch. Med., Vanderbilt Univ., Nashville, TN, 37232, USA  
SO Xenobiotica (1990), 20(8), 779-86  
CODEN: XENOBH; ISSN: 0049-8254  
DT Journal  
LA English  
IT **125481-61-0**  
RL: FORM (Formation, nonpreparative)  
(formation of, as buspirone metabolite)  
RN 125481-61-0 CAPLUS  
CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-  
piperazinyl]butyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1990:111428 CAPLUS  
 DN 112:111428  
 TI Metabolism of the antianxiety drug buspirone in human subjects  
 AU Jajoo, Hemant K.; Mayol, Robert; LaBudde, John A.; Blair, Ian A.  
 CS Sch. Med., Vanderbilt Univ., Nashville, TN, 37232, USA  
 SO Drug Metabolism and Disposition (1989), 17(6), 634-40  
 CODEN: DMDSAI; ISSN: 0090-9556  
 DT Journal  
 LA English  
 IT **125481-59-6 125481-60-9 125481-61-0**  
 RL: BIOL (Biological study)  
 (as buspirone metabolite, in human urine)  
 RN 125481-59-6 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(5-hydroxy-2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 125481-60-9 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(5-hydroxy-4-methoxy-2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 125481-61-0 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)







L5 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1990:111427 CAPLUS  
 DN 112:111427  
 TI Metabolism of the antianxiety drug buspirone in the rat  
 AU Jajoo, Hemant K.; Mayol, John A.; LaBudde, John A.; Blair, Ian A.  
 CS Cent. Mol. Toxicol., Vanderbilt Univ., Nashville, TN, 37232, USA  
 SO Drug Metabolism and Disposition (1989), 17(6), 625-33  
 CODEN: DMDSAI; ISSN: 0090-9556  
 DT Journal  
 LA English  
 IT **125481-59-6 125481-60-9 125481-61-0**  
 RL: BIOL (Biological study)  
 (as buspirone metabolite)  
 RN 125481-59-6 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(5-hydroxy-2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 125481-60-9 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(5-hydroxy-4-methoxy-2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 125481-61-0 CAPLUS  
 CN 8-Azaspiro[4.5]decane-7,9-dione, 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



10/636,070

10/636,070

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

62.57

218.20

STN INTERNATIONAL LOGOFF AT 17:33:38 ON 07 OCT 2004